

APOLLO HOSPITALS ENTERPRISE LIMITED



CIN : L85110TN1979PLC008035

6th November 2024

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
Scrip Code- APOLLOHOSP
ISIN INE437A01024

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

This has reference to our letters dated 26th September and 14th October 2024, regarding the captioned subject. The Board at its meeting held today transacted the following items of business.

1. Unaudited financial results (both standalone and consolidated) of the Company for the three and six months ended 30th September 2024, which have been subjected to Limited Review by the Statutory Auditors of the Company - as Annexure I.
2. Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
3. The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.
4. The said documents are being posted on the website of the Company i.e., www.apollohospitals.com.

You are requested to kindly take note of the same.

The meeting of the Board of Directors commenced at 11.00 a.m and concluded at 3:30 p.m.

Please take note of the same in your records.

Thanking You

Yours faithfully
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT - FINANCE
AND COMPANY SECRETARY

IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three and six months ended September 30, 2024

(Rs. in Million)

Particulars	Three months ended 30/09/2024	Preceeding Three months ended 30/06/2024	Corresponding Three months ended 30/09/2023	Year to date figures for current period ended 30/09/2024	Year to date figures for previous period ended 30/09/2023	Previous year ended 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from operations	21,354	19,366	18,665	40,720	35,549	72,738
(b) Other income	1,209	273	646	1,482	824	1,799
Total Income (a + b)	22,563	19,639	19,311	42,202	36,373	74,537
2 Expenses						
(a) Cost of materials consumed	5,809	5,362	5,142	11,171	9,759	19,990
(b) Employee benefits expense	4,124	3,807	3,578	7,931	6,912	14,252
(c) Finance costs	654	635	596	1,289	1,205	2,498
(d) Depreciation and amortisation expenses	1,083	1,029	934	2,112	1,865	3,990
(e) Other expenses	6,018	5,489	5,154	11,507	9,910	20,521
Total Expenses	17,688	16,322	15,404	34,010	29,651	61,251
3 Profit before Exceptional item and tax (1) - (2)	4,875	3,317	3,907	8,192	6,722	13,286
4 Exceptional Items	-	-	-	-	-	-
5 Profit before tax (3) + (4)	4,875	3,317	3,907	8,192	6,722	13,286
6 Tax expense						
Current tax	1,201	811	1,036	2,012	1,772	3,216
Deferred tax	(22)	(11)	(77)	(33)	(139)	(35)
7 Profit after tax for the period / year (5) - (6)	3,696	2,517	2,948	6,213	5,089	10,105
8 Other Comprehensive Income/(Loss)						
Items that will not be reclassified to Profit or Loss						
Remeasurement gains/(losses) on defined benefit plans	(32)	67	(107)	35	(128)	(114)
Income tax relating to items that will not be reclassified to profit or loss	8	(17)	27	(9)	32	29
Total Other Comprehensive Income/ (Loss)	(24)	50	(80)	26	(96)	(85)
9 Total Comprehensive Income for the period/year (7) + (8)	3,672	2,567	2,868	6,239	4,993	10,020

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited
Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three and six months ended September 30, 2024

Particulars	Three months ended 30/09/2024	Preceeding Three months ended 30/06/2024	Corresponding Three months ended 30/09/2023	Year to date figures for current period ended 30/09/2024	Year to date figures for previous period ended 30/09/2023	Previous year ended 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
10 Paid-up equity share capital (Face value Rs.5/- per share)				719	719	719
11 Reserves (excluding Revaluation reserves)				81,185	72,225	76,390
12 Earnings per equity share of Rs.5/- each Basic and Diluted EPS for the period/year (Rs.)	*25.71	*17.51	*20.50	*43.21	*35.39	70.28
Additional Information :- Earnings before finance costs, tax, depreciation and amortization, Other income, exceptional items (EBITDA) (Refer Foot Note 1)	5,403	4,708	4,791	10,111	8,968	17,975

*Not annualised

Foot Notes:

- 1 The Company has presented Earnings before Finance costs, Tax, Depreciation, Amortization, Other income and Exceptional items (EBITDA) additionally as part of Standalone Financial Results.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Standalone Balance Sheet (Refer note 5)

(Rs. in Million)

Particulars	As at 30-Sep-24 Unaudited	As at 31-Mar-24 Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	46,563	47,096
(b) Right-of-Use Assets	12,969	12,612
(c) Capital work-in-progress	2,954	1,725
(d) Other Intangible assets	811	608
(e) Intangible assets under development	249	272
(f) Financial Assets		
(i) Investments	24,669	19,377
(ii) Loans	3,600	2,446
(iii) Other financial assets	1,585	1,789
(g) Income Tax Asset (Net)	581	729
(h) Other Non-Current Assets	795	647
Total Non - Current Assets	94,776	87,301
Current assets		
(a) Inventories	1,268	1,187
(b) Financial assets		
(i) Investments	6,974	6,835
(ii) Trade receivables	8,825	8,083
(iii) Cash and cash equivalents	3,247	2,761
(iv) Bank balances other than (iii) above	3,769	661
(v) Loans	1,126	791
(vi) Other financial assets	5,467	13,673
(c) Contract Assets	1,133	878
(d) Other current assets	1,913	1,882
Total Current Assets	33,722	36,751
Total Assets	128,498	124,052
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	719	719
(b) Other Equity	81,185	76,390
Total Equity	81,904	77,109
Liabilities		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	16,814	17,855
(ii) Lease liabilities	11,568	11,563
(iii) Other financial liabilities	24	23
(b) Deferred tax liabilities (Net)	3,739	3,764
(c) Other non-current liabilities	13	36
Total Non - Current Liabilities	32,158	33,241
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,051	1,702
(ii) Lease liabilities	1,269	1,098
(iii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	321	586
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	7,325	6,989
(iv) Other financial liabilities	1,103	1,236
(b) Other current liabilities	1,135	1,078
(c) Provisions	1,232	1,013
Total Current Liabilities	14,436	13,702
Total Liabilities	46,594	46,943
Total Equity and Liabilities	128,498	124,052

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director


Apollo Hospitals Enterprise Limited
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Unaudited Statement of Standalone Cash Flows (Refer note 5)

(Rs. in Million)

PARTICULARS	For the period ended 30-Sep-24	For the period ended 30-Sep-23
Cash flow from operating activities		
Profit after tax for the period	6,213	5,089
Operating Profit before working capital changes	10,323	9,215
Net cash generated from operating activities (A)	15,858	6,666
Net cash used in investing activities (B)	(11,827)	(4,092)
Net cash used in financing activities (C)	(3,545)	(2,200)
Net Increase in cash and cash equivalents (A+B+C) = (D)	486	374
Cash and cash equivalents at the beginning of the period (E)	2,761	2,170
Cash and cash equivalents at the end of the period (D) +(E)	3,247	2,544
Cash and cash equivalents comprises of		
- Cash on hand	65	44
- Balance with banks	3,182	2,500
Total cash and cash equivalents at the end of the period	3,247	2,544

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

NOTES TO THE STANDALONE FINANCIAL RESULTS:

1. The standalone financial results ("the statement") of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 5, 2024 and November 6, 2024 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three and six months ended September 30, 2024.
2. Apollo Healthco Limited (AHL), an unlisted material subsidiary had issued 3,43,629 (three lakhs forty-three thousand six hundred twenty-nine) equity shares, each having face value of INR 10 (Indian Rupees Ten only) and premium of INR 11,630.45 (Indian Rupees Eleven Thousand Six Hundred Thirty and Forty-Five Paise only), aggregating to Rs. 3,999.99 million on a preferential basis, to the Company.
3. On 10th September 2024, AHL had allotted 39,92,64,575 (thirty-nine crore ninety-two lakh sixty four thousand five hundred and seventy five) fully paid up bonus equity shares, each having face value of INR 10 (Indian Rupees Ten only), to the Company.
4. The Board of Directors at its meeting held on 3rd August 2024, have approved the formulation of the Apollo ESOP 2024, with the authority to grant not exceeding 21,56,770 (1.50 % of the paid up capital as on 31 March 2024) employee stock options to such Eligible Employees of the Company and its subsidiaries, associate companies, joint ventures, and group companies, as may be determined by the Nomination and Remuneration Committee (also designated as Compensation Committee), in one or more tranches, from time to time, which in aggregate shall be exercisable into not more than 21,56,770 equity shares of face value of Rs. 5/- (Rupees Five Only) each fully paid-up. Apollo ESOP 2024 was approved by the shareholders at the AGM of the Company held on 30th August 2024.
5. The standalone balance sheet as at September 30, 2024 and the condensed statement of cash flows for the half year ended September 30, 2024 are provided as annexure to this statement.
6. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai
Date: November 6, 2024

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Apollo Hospitals Enterprise Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Company"), for the three months and six months ended September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Digitally signed by
NACHIAPPAN
SUBRAMANIAN
Date: 2024.11.06 14:58:40
+05'30'
Nachiappan Subramanian
(Partner)
(Membership No. 218727)

Place: Chennai
Date: November 06, 2024

Apollo Hospitals Enterprise Limited
Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Unaudited Consolidated Financial Results for the three and six months ended September 30, 2024

(Rs. in Million)

Particulars	Three months ended 30/09/2024	Preceeding Three months ended 30/06/2024	Corresponding Three months ended 30/09/2023	Year to date figures for current period ended 30/09/2024	Year to date figures for previous period ended 30/09/2023	Previous year ended 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from operations	55,893	50,856	48,469	106,749	92,647	190,592
(b) Other income	382	372	222	754	504	1,063
Total Income (a + b)	56,275	51,228	48,691	107,503	93,151	191,655
2 Expenses						
(a) Cost of materials consumed	7,443	6,901	6,325	14,344	12,133	24,541
(b) Purchases of Stock-in-trade	21,104	19,107	18,405	40,211	35,272	73,849
(c) Changes in inventories of stock-in-trade	30	222	(145)	252	(138)	(335)
(d) Employee benefits expense	7,001	6,581	6,441	13,582	12,359	24,937
(e) Finance costs	1,175	1,164	1,113	2,339	2,175	4,494
(f) Depreciation and amortisation expense	1,845	1,774	1,634	3,619	3,303	6,870
(g) Other expenses	12,160	11,294	11,168	23,454	21,656	43,693
Total Expenses	50,758	47,043	44,941	97,801	86,760	178,049
3 Profit/(loss) before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)	5,517	4,185	3,750	9,702	6,391	13,606
4 Share of profit/(loss) of an associates / a joint ventures	57	115	21	172	80	180
5 Profit before exceptional item and tax (3) + (4)	5,574	4,300	3,771	9,874	6,471	13,786
6 Exceptional item (Refer note 5)	-	-	19	-	19	19
7 Profit before tax (5) + (6)	5,574	4,300	3,790	9,874	6,490	13,805
8 Tax Expenses						
Current tax	1,598	1,130	1,325	2,728	2,349	4,368
Deferred tax	19	15	(23)	34	(81)	87
9 Profit/(Loss) for the period/year (7) - (8)	3,957	3,155	2,488	7,112	4,222	9,350

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited
Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Unaudited Consolidated Financial Results for the three and six months ended September 30, 2024

Particulars	(Rs. in Million)					
	Three months ended 30/09/2024	Preceding Three months ended 30/06/2024	Corresponding Three months ended 30/09/2023	Year to date figures for current period ended 30/09/2024	Year to date figures for previous period ended 30/09/2023	Previous year ended 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
10 Other Comprehensive Income						
Items that will not be reclassified to Profit or Loss						
Remeasurement gains / (losses) on defined benefit plan	(66)	52	(130)	(14)	(151)	(142)
Income tax relating to items that will not be reclassified to profit or loss	9	-	33	9	38	36
Items that will be reclassified to Profit or Loss						
Exchange differences in translating the financial statements of foreign operations	2	(0)	4	1	3	2
Total Other Comprehensive Income / (Expense)	(55)	52	(93)	(4)	(110)	(104)
11 Total Comprehensive Income / (Expense) for the period/year (after tax) (9) + (10)	3,902	3,207	2,395	7,108	4,112	9,246
Profit / (Loss) for the period attributable to:						
Owners of the parent	3,788	3,052	2,329	6,840	3,995	8,986
Non-controlling interest	169	103	159	272	227	364
Other Comprehensive Income / (Expense) for the period attributable to:						
Owners of the parent	(48)	52	(92)	3	(109)	(102)
Non-controlling interest	(7)	-	(1)	(7)	(1)	(2)
Total Comprehensive Income / (Expense) for the period attributable to:						
Owners of the parent	3,740	3,104	2,237	6,843	3,886	8,884
Non-controlling interest	162	103	158	265	226	362
12 Paid-up equity share capital (Face value Rs.5/- per share)				719		719
Reserves (excluding Revaluation Reserves)				74,214		68,557
13 Earnings per equity share of Rs.5/- each						
Basic and Diluted EPS for the period/year (RS.)	*26.34	*21.23	*16.20	*47.57	*27.78	62.50

*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu
Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. in Million)

Particulars	Three months ended 30/09/2024	Preceding Three months ended 30/06/2024	Corresponding Three months ended 30/09/2023	Year to date figures for current period ended 30/09/2024	Year to date figures for previous period ended 30/09/2023	Previous year ended 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a) Healthcare Services	29,204	26,536	25,659	55,741	48,766	99,392
b) Retail Health & Diagnostics	4,039	3,661	3,542	7,700	6,730	13,643
c) Digital Health & Pharmacy distribution	22,822	20,821	19,454	43,643	37,508	78,269
d) Others	12	12	12	24	23	47
SUB - TOTAL	56,077	51,030	48,667	107,108	93,027	191,351
Less : Intersegmental Revenue	184	174	198	359	380	759
Income from Operations	55,893	50,856	48,469	106,749	92,647	190,592
2. Segment Results						
a) Healthcare Services	5,813	4,902	5,179	10,715	9,404	18,464
b) Retail Health & Diagnostics	117	27	30	144	(72)	(15)
c) Digital Health & Pharmacy distribution	389	73	(512)	461	(1,199)	(1,309)
d) Others	(9)	(25)	(56)	(33)	(70)	(103)
SUB - TOTAL	6,310	4,977	4,641	11,287	8,063	17,037
Less: (i) Finance Cost	1,175	1,164	1,113	2,339	2,175	4,494
Add: (ii) Other un-allocable income, (net of expenditure)	382	372	222	754	504	1,063
Add: (iii) Exceptional Item	-	-	19	-	19	19
Add: (iv) Share of profit/(loss) of associates / joint ventures	57	115	21	172	80	180
Profit Before Tax	5,574	4,300	3,790	9,874	6,490	13,805
3. Capital employed						
a) Healthcare Services *						
Segment Assets	127,657	117,049	105,778	127,657	105,778	114,522
Segment Liabilities	(39,779)	(36,097)	(31,635)	(39,779)	(31,635)	(35,651)
b) Retail Health & Diagnostics						
Segment Assets	12,583	13,218	11,860	12,583	11,860	11,574
Segment Liabilities	(10,542)	(9,620)	(9,958)	(10,542)	(9,958)	(9,792)
c) Digital Health & Pharmacy distribution						
Segment Assets	33,540	24,099	22,130	33,540	22,130	23,806
Segment Liabilities	(12,374)	(11,383)	(10,269)	(12,374)	(10,269)	(12,367)
d) Others						
Segment Assets	288	294	311	288	311	304
Segment Liabilities	(176)	(175)	(184)	(176)	(184)	(188)
e) Unallocated						
Segment Assets	21,411	15,907	15,530	21,411	15,530	17,325
Segment Liabilities	(53,462)	(36,209)	(34,787)	(53,462)	(34,787)	(36,328)
Total	79,146	77,083	68,776	79,146	68,776	73,205
* Includes Capital employed in various hospital projects under construction	10,702	8,998	7,399	10,702	7,399	8,729

APOLLO HOSPITALS ENTERPRISE LTD

Suneeta Reddy
SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Consolidated Balance Sheet (Refer note 7)

(Rs. in Million)

Particulars	As at 30-Sep-24 Unaudited	As at 31-Mar-24 Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	66,449	65,662
(b) Right Of Use Asset	23,978	19,743
(c) Capital work-in-progress	10,417	8,447
(d) Investment Property	31	34
(e) Goodwill	10,123	10,123
(f) Other Intangible assets	1,147	1,077
(a) Intangible assets under development	285	281
(h) Financial Assets		
(i) Investments in Equity accounted investee	2,067	1,984
(ii) Investments	1,068	1,037
(iii) Loans	309	66
(iv) Other financial assets	2,849	2,525
(i) Deferred tax assets	94	109
(i) Income Tax assets (Net)	1,964	2,424
(k) Other non-current assets	1,316	1,222
Total non - current assets	122,097	114,734
Current assets		
(a) Inventories	4,482	4,598
(b) Financial assets		
(i) Investments	6,980	6,840
(ii) Trade receivables	28,804	25,149
(iii) Cash and cash equivalents	14,353	5,055
(iv) Bank balances	7,750	4,283
(v) Loans	30	49
(vi) Other financial assets	5,357	1,659
(c) Contract assets	1,867	1,459
(d) Other current assets	3,759	3,705
Total current assets	73,382	52,797
Total Assets	195,479	167,531
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	719	719
(b) Other Equity	74,292	68,635
Equity attributable to owners of the Company	75,011	69,354
Non-controlling Interests	4,135	3,851
Total Equity	79,146	73,205
Liabilities		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	38,194	22,356
(ii) Lease liabilities	22,525	19,814
(iii) Other financial liabilities	91	103
(b) Provisions	814	732
(c) Deferred tax liabilities	4,515	4,498
(d) Other non-current liabilities	180	178
Total Non - Current Liabilities	66,319	47,681
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	10,291	9,263
(ii) Lease liabilities	2,700	1,893
(iii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises: and	707	848
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	23,588	22,838
(iv) Other financial liabilities	8,398	7,987
(b) Other current liabilities	2,667	2,369
(c) Provisions	1,655	1,434
(d) Current Tax Liabilities	8	13
Total Current Liabilities	50,014	46,645
Total Liabilities	116,333	94,326
Total Equity and Liabilities	195,479	167,531

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Unaudited Statement of Consolidated Cash Flow (Refer note 7)

PARTICULARS	(Rs. in Million)	
	For the period ended 30-Sep-2024	For the period ended 30-Sep-2023
Cash flow from Operating Activities		
Profit for the year	7,112	4,222
Operating Profit before working capital changes	15,826	12,636
Net cash generated from operating activities (A)	6,865	9,603
Net cash (used in) / generated from Investing Activities (B)	(10,105)	(8,365)
Net cash (used in) / generated from Financing Activities (C)	12,538	(849)
Net Increase in cash and cash equivalents (A+B+C) = (D)	9,298	389
Cash and cash equivalents at the beginning of the year (E)	5,055	4,334
Add: Cash inflow due to Acquisition of controlling stake in Joint Venture	-	1
Cash and cash equivalents at the end of the year (D) +(E)	14,353	4,724
Cash and cash equivalents comprises of		
- Cash on hand	110	105
- Balance with banks	14,243	4,619
Total cash and cash equivalents at the end of the period	14,353	4,724

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

NOTES TO THE CONSOLIDATED FINANCIAL RESULTS:

1. The consolidated financial results ("the statement") of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 5, 2024 and November 6, 2024 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three and six months ended September 30, 2024.
2. Apollo Hospitals Worli LLP, the Company's subsidiary has entered into a long-term definitive agreement with Konkan Unnati Mitra Mandal (KUMM), a public trust registered under the Maharashtra Public Trusts Act, 1950 for the establishment of a 500-bed healthcare facility in Worli, Mumbai, which will be undertaken through a Build, Operate and Manage project and consequently Apollo Hospitals Worli LLP had recognized right of use assets amounting to Rs.3,554 Million.
3. The Board of Directors at its meeting held on 3rd August 2024, have approved the formulation of the Apollo ESOP 2024, with the authority to grant not exceeding 21,56,770 (1.50 % of the paid up capital as on 31 March 2024) employee stock options to such Eligible Employees of the Company and its subsidiaries, associate companies, joint ventures, and group companies, as may be determined by the Nomination and Remuneration Committee (also designated as Compensation Committee), in one or more tranches, from time to time, which in aggregate shall be exercisable into not more than 21,56,770 equity shares of face value of Rs. 5/- (Rupees Five Only) each fully paid-up. Apollo ESOP 2024 was approved by the shareholders at the AGM of the Company held on 30th August 2024.
4. On 27th September 2024, Apollo Healthco Limited (AHL), an unlisted material subsidiary, approved and allotted the following securities to Rasmeli Limited (an affiliate of Advent International Corporation) : -
 - (a) 1 (one) equity share of face value of Rs. 10/- each at a premium of Rs. 272.31 per share aggregating an amount of Rs. 282.31.
 - (b) 14,85,00,000 Class A fully and compulsorily convertible non-cumulative participating preference shares, (Class A CCPS) of face value of Rs. 100/- per share aggregating to Rs. 14,850 million, on the terms set out in the Investment Agreement between the Company, AHL, Rasmeli Ltd and Ms. Shobana Kamineni (promoter) as fully paid-up shares.
 - (c) 9,90,00,000 partly paid-up Class B fully and compulsorily convertible non-cumulative participating preference shares (Class B CCPS) of face value of Rs.100/- per share aggregating to Rs. 9,900 million, on the terms set out in the Investment agreement with Rs. 25/- per share aggregating to Rs. 2,475 million to Rasmeli Limited called in the first tranche, and the remaining Rs. 75 per share aggregating to Rs.7,425 million will be paid by Rasmeli Limited, in the second tranche at the time of being called upon by the Board of AHL, towards making Class B CCPS fully paid up.

The investment received from Rasmeli Limited, in AHL in the form of Compulsorily Convertible Preference shares (CCPs) is recorded as a financial liability under IND

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

AS 32, as the CCPs has variability in conversion terms pursuant to certain adjustments in accordance with the Investment agreement.

5. On August 7, 2023, Apollo Hospitals International Limited (AHIL), a subsidiary company of the Company had acquired additional 50% stake in Amrishi Oncology Services Private Ltd (AOSPL). Consequently, AOSPL became a subsidiary of AHIL with effect from the said date. The Subsidiary Company determined a purchase price allocation based on the amounts of the identifiable assets acquired and liabilities assumed, resulting in a goodwill of Rs.274 million. The acquisition date fair value of the existing equity interest in AOSPL compared to its carrying amount resulted in a gain of Rs.19 million, which has been included under exceptional item for the half year ended September 30, 2023.
6. The Honourable High Court of Karnataka on October 8, 2021 set aside the order of the State of Karnataka, Revenue Department ("Revenue Department") initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company alleging non-compliance of certain conditions associated with the allotment of land to the said subsidiary company and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated 9 February 2022 seeking explanations as to why the original order needs to be withdrawn for which the subsidiary company had filed a detailed response explaining that there were no violations of the conditions relating to the allotment of the land. Based on legal opinion received, the subsidiary company has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.
7. The consolidated balance sheet as at September 30, 2024 and the condensed statement of cash flows for the half year ended September 30, 2024 are provided as annexure to this statement.
8. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai
Date: November 6, 2024

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
Apollo Hospitals Enterprise Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income (net) of its associates and joint ventures for the three months and six months ended September 30, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary

**Deloitte
Haskins & Sells LLP**

Name of the Company	Relationship
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Apollomedics International Lifesciences Limited	Subsidiary
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary
Health Axis Private Limited (HAPL)	Subsidiary
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Apollo Fertility Centre Private Limited	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Apollo 24/7 Insurance Services Limited	Subsidiary of AHL
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollo CVHF Limited	Subsidiary of AHIL
Apollo-Amrish Oncology Services Private Limited (Refer Note 5)	Subsidiary of AHIL
Baalayam Healthcare Private Limited	Subsidiary of KFHS
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Apollo Gleneagles PET-CT Private Limited	Joint venture
ApoKos Rehab Private Limited	Joint venture
Nexify Health Private Limited	Joint venture of HAPL

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other

**Deloitte
Haskins & Sells LLP**

accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note 6 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter.
7. We did not review the interim financial results/financial information of 25 subsidiaries included in the consolidated unaudited financial results, whose interim financial results/financial information reflect total assets of Rs. 28,694 million as at September 30, 2024 and, total revenues of Rs. 4,538 million and Rs. 8,603 million for the three months and six months ended September 30, 2024 respectively, total net profit after tax of Rs. 347 million and Rs. 623 million for the three months and six months ended September 30, 2024 respectively and total comprehensive income (net) of Rs. 331 million and Rs. 607 million for the three months and six months ended September 30, 2024 respectively and net cash flows Rs. 419 million for the six months ended September 30, 2024, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 57 million and Rs. 172 million for the three months and six months ended September 30, 2024 respectively and total comprehensive income (net) of Rs. 55 million and Rs. 174 million for the three months and six months ended September 30, 2024, as considered in the Statement, in respect of 2 joint ventures and 5 associates (including 2 subsidiaries of 1 associate), whose interim financial results/financial information have not been reviewed by us. These interim financial results/financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

8. The consolidated unaudited financial results includes the interim financial results/financial information of 6 subsidiaries which have not been reviewed by their auditors, whose interim financial results/financial information reflect total assets of Rs. 320 million as at September 30, 2024 and, total revenue of Rs. Nil and Rs. Nil for the three months and six months ended September 30, 2024 respectively, total loss after tax of Rs. 1 million and Rs. 2 million for the three months and six months ended September 30, 2024 respectively and total comprehensive loss of Rs. 2 million and Rs. 3 million for the three months and six months ended September 30, 2024 respectively and net cash flows of Rs. Nil for the six months ended September 30, 2024, as considered in the Statement. The consolidated unaudited financial information also includes the Group's share of profit after tax of Rs. Nil and Rs. Nil for the three months and six months ended September 30, 2024 respectively and total comprehensive income of Rs. Nil and Rs. Nil for the three months and six months ended September 30, 2024, as considered in the Statement, in respect of 1 associate and 1 joint venture, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results/financial information are not material to the Group.

**Deloitte
Haskins & Sells LLP**

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial results/financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

NACHIAPPAN Digitally signed by
NACHIAPPAN
SUBRAMANI SUBRAMANIAN
AN Date: 2024.11.06
14:59:44 +05'30'
Nachiappan Subramanian
Partner
(Membership No. 218727)

Place: Chennai
Date: November 06, 2024

// PRESS RELEASE //



06th November 2024

Apollo Hospitals announces Q2 FY25 results:

Q2 Consolidated Revenues grew 15% YoY to Rs 5,589 Crores

Q2 Consolidated EBITDA grew 30% YoY to Rs 816 Crores

Q2 Consolidated PAT grew 63% YoY to Rs 379 Crores

Apollo Hospitals reaffirmed its commitment to bringing quality healthcare to the people of Maharashtra by entering into a definitive agreement to Build and Operate a 500-bed hospital to be established in Worli, Mumbai.

Apollo Hospitals also announced the expansion of its existing hospital facility in Lucknow to 500 beds from the present 300 beds by adding another 200 beds, to be developed on their recent acquisition of a 1.2-acre land.

With these 2 additions, Apollo Hospitals now has plans to add over 3512 total beds (2877 census beds) over the next 4 years across 11 locations in India.

Dr. Prathap C Reddy, Founder & Chairman, Apollo Hospitals Group said,

"At Apollo Hospitals, we are dedicated to continually evolving to meet the changing healthcare needs of our nation. Through strategic initiatives like our investment in Apollo Health and Lifestyle and the launch of new multi-specialty hospitals, we reaffirm our commitment to expanding access to high-quality healthcare across India, particularly in regions where critical care access is essential.

One of our proudest achievements is our recent partnership with the Government of Tripura to provide free heart surgeries for children, underscoring our belief that healthcare should reach those who need it most, especially in underserved communities. Beyond expanding access, we are advancing medical technology with innovative treatments like water vapor thermotherapy for prostate care and robotic radiosurgery systems for cancer. These state-of-the-art solutions make procedures less invasive and reduce recovery time, resulting in better patient outcomes.

We're also investing in the future of healthcare with the launch of our new research academy, which is focused on driving groundbreaking medical discoveries that will shape the next generation of treatments. Our priorities remain clear—enhancing patient care, prioritizing safety, and advancing medical science.

The first half of FY25 has been an exciting time for us, marked by these major milestones aimed at extending the reach and impact of our healthcare services. Moving forward, our mission is simple: to push the boundaries of healthcare and ensure that everyone, regardless of where they live, has access to the best medical services. This is our promise, and we are committed to making it a reality."

Q2 FY25 CONSOLIDATED RESULTS

REVENUE

Q2 FY25 Revenues grew to Rs. 5,589 Crores; 15% YoY growth

- Healthcare Services (HCS) Revenue at Rs. 2,903 Crore; 14% YoY growth
- AHLL: Revenues at Rs. 404 Crores; 14% YoY growth
- Apollo HealthCo: Pharmacy Distribution & Digital Health Revenues at Rs. 2,282 Crores; 17% YoY growth
- GMV of Apollo 24/7 at Rs. 757 Crores

EBITDA

Q2 FY25 Consolidated EBITDA stood at Rs. 816 Crores; 30% YoY growth

- Healthcare Services (HCS) EBITDA at Rs. 722 Crores; YoY growth of 14%
- AHLL EBITDA at Rs. 41 Crores; YoY growth of 30%
- Apollo HealthCo: Pharmacy distribution & Digital health EBITDA at Rs. 52 Crores

PAT

Q2 FY25 Consolidated PAT Rs. 379 Crores, compared to Rs. 233 Crores in Q2 FY24; 63% YoY growth

- Healthcare Services (HCS) PAT at Rs. 364 Crore; YoY growth of 16%

H1 FY25 CONSOLIDATED RESULTS

REVENUE

H1 FY25 Revenues grew to Rs. 10,675 Crores; 15% YoY growth

- Healthcare Services (HCS) Revenue at Rs. 5,541 Crores; 14% YoY growth
- AHLL: Revenues at Rs. 770 Crores; 14% YoY growth
- Apollo HealthCo: Pharmacy Distribution & Digital Health Revenues at Rs. 4,364 Crores; 16% YoY growth
- GMV of Apollo 24/7 at Rs. 1,452 Crores

EBITDA

H1 FY25 Consolidated EBITDA stood at Rs. 1,491 Crores; 31% YoY growth

- Healthcare Services (HCS) EBITDA at Rs. 1,344 Crores; YoY growth of 14%
- AHLL EBITDA at Rs. 72 Crores; YoY growth of 31%
- Apollo HealthCo: Pharmacy distribution & Digital health EBITDA at Rs. 75 Crores

PAT

H1 FY25 Consolidated PAT Rs. 684 Crores, compared to Rs. 400 Crores in H1 FY24; 71% YoY growth

- Healthcare Services (HCS) PAT at Rs. 693 Crore; YoY growth of 20%

Financial Performance – Q2 FY25

Consolidated Q2 FY25 Performance

- Revenues at Rs.55,893 mn vs Rs.48,469 mn in Q2 FY24; growth of 15% YoY
- EBITDA at Rs.8,155 mn vs Rs.6,275 mn in Q2 FY24. This is after Apollo 24/7 cost of Rs 1,353 mn in the quarter (including Rs 156 mn non-cash ESOP charge) vs Rs 1,973 mn in Q2 FY24.
- Reported PAT at Rs.3,788 mn vs Rs.2,329 mn in Q2 FY24
- Diluted EPS of Rs.26.34 per share in Q2 FY25 (not annualized)

Healthcare service Q2 FY25 Performance

- Revenue at Rs.29,032 mn vs Rs 25,472 mn in Q2 FY24; growth of 14% YoY
- EBITDA grew by 14% at Rs.7,220 mn vs Rs.6,344 mn in Q2 FY24; Margins at 24.87% in Q2 FY25
- PAT stood at Rs.3,643 mn vs Rs.3,136 mn in Q2 FY24, 16% growth

Apollo Health and Lifestyle Limited Q2 FY25 Performance

- Revenue at Rs. 4,039 mn vs Rs.3,542 mn in Q2 FY24; growth of 14% YoY
- EBITDA grew by 30% at Rs.414 mn vs Rs. 318 mn in Q2 FY24; Margins at 10.26% in Q2 FY25
- PAT loss of Rs.46 mn vs loss of Rs.130 mn in Q2 FY24

Apollo HealthCo Q2 FY25 Performance

- Revenue at Rs.22,822 mn vs Rs.19,454 mn in Q2 FY24; growth of 17% YoY
- EBITDA at Rs.521 mn vs loss of Rs.387mn in Q2 FY24; Margins at 2.28% in Q2 FY25
- PAT stood at Rs.190 mn vs loss of Rs.678 mn in Q2 FY24

Financial Performance – H1 FY25

Consolidated H1 FY25 Performance

- Revenues at Rs. 106,749 mn vs Rs. 92,647 mn in H1 FY24; growth of 15% YoY
- EBITDA at Rs.14,906 mn vs Rs.11,365 mn in H1 FY24. This is after Apollo 24/7 cost of Rs 2,849 mn (including Rs 352 mn non-cash ESOP charge) vs Rs. 4,012 mn in H1 FY24.
- Reported PAT at Rs.6,840 mn vs Rs. 3,995 mn in H1 FY24.
- Diluted EPS of Rs. 47.57 per share in H1 FY25 (not annualized)

Healthcare service H1 FY25 Performance

- Revenue at Rs. 55,405 mn vs Rs. 48,409 mn in H1 FY24; growth of 14% YoY
- EBITDA grew by 14% at Rs.13,437 mn vs Rs. 11,767 mn in H1 FY24; Margins at 24.25% in H1 FY25
- PAT stood at Rs. 6,927 mn vs Rs. 5,775 mn in H1 FY24, 20% growth

Apollo Health and Lifestyle Limited H1 FY25 Performance

- Revenue at Rs. 7,700 mn vs Rs.6,730 mn in H1 FY24; growth of 14% YoY
- EBITDA grew by 31% at Rs.723 mn vs Rs.550 mn in H1 FY24; Margins at 9.39% in H1 FY25
- PAT loss of Rs.147 mn vs loss of Rs.277 mn in H1 FY24

Apollo HealthCo H1 FY25 Performance

- Revenue at Rs.43,643 mn vs Rs.37,508 mn in H1 FY24; growth of 16% YoY
- EBITDA at Rs.746 mn vs loss of Rs.953 mn in H1 FY24; Margins at 1.71 % in H1 FY25
- PAT stood at Rs.61 mn vs loss of Rs.1,503 mn in H1 FY24

Q2 FY25 Segment-wise Performance Update

Healthcare Services (Hospitals)

As on September 30, 2024, Apollo Hospitals had 7,994 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 73% vs 68% in the same period in the previous year, aided by a strong increase in patient flows across hospitals.

Consolidated Revenues of the healthcare services division increased by 14% to Rs.29,032 million in Q2 FY25 compared to Rs.25,472 million in Q2 FY24.

EBITDA (Post Ind AS 116) was at Rs.7,220 million in Q2 FY25 compared to Rs. 6,344 million in Q2 FY24. EBITDA was higher by 14 % YoY.

Revenues in the **Tamil Nadu cluster** grew by 9%, IP Volumes grew by 4%. ARPOB grew by 6% to Rs. 79,224. Overall occupancy in the cluster was 1,311 beds (64% occupancy) as compared to 1,266 beds (62% occupancy) in the previous year.

In **AP Telangana region**, Revenues grew by 22%, IP volumes grew by 18%. ARPOB grew by 2% to Rs.57,217. Occupancy in the cluster was 924 beds (74% occupancy) as compared to 768 beds (60% occupancy) in the previous year.

In **Karnataka region**, Revenues grew by 17%, IP volumes grew by 12%. ARPOB degrew by 1% to Rs.60,325. Occupancy in the cluster was 620 beds (80% occupancy) as compared to 522 beds (73% occupancy) in the previous year.

In **Eastern region**, Revenues grew by 13%, IP volumes grew by 8%. ARPOB grew by 4% to Rs.45,860. Occupancy in the cluster was 1,487 beds (80% occupancy) as compared to 1,365 beds (77% occupancy) in the previous year.

In **Western region**, Revenues grew by 10%, IP volumes grew by 4%. ARPOB degrew by 1% to Rs.45,471. Occupancy in the cluster was 585 beds (67% occupancy) as compared to 526 beds (61% occupancy) in the previous year.

In **Northern region**, Revenues grew by 12%, IP volumes grew by 8%. ARPOB grew by 5% to Rs.62,290. Occupancy in the cluster was 896 beds (74% occupancy) as compared to 840 beds (77% occupancy) in the previous year.

Apollo Health and Lifestyle Limited: Diagnostics and Retail Healthcare

- AHLL Gross Revenue at Rs.4,039 million; 14% YoY growth
- Diagnostics Revenue stood at Rs.1,345 million and Spectra at Rs.711 million

Apollo HealthCo: Digital Healthcare and Omni-channel Pharmacy platform

- Offline Pharmacy distribution revenues at Rs. 20,144 million in Q2 FY25 while Revenues from Digital platform were at Rs. 2,678 million
- Overall Health Co Revenues were at Rs 22,822 million representing 17% YoY growth.
- 154 net new stores were opened in this quarter, taking the total number to 6,228 stores.
- GMV of Apollo 24/7 at Rs 7,569 million in Q2 FY25, growth of 2% over Q2 FY24.
- Avg Q2 FY25 run rate of 76K/day order across Pharma, Diagnostics Consultations (including IP/OP referrals) compared to 62K/day in Q2 FY24.

CLINICAL EXCELLENCE HIGHLIGHTS

- Apollo Hospitals implemented oxygen therapy to prevent foot amputation, showcasing its commitment to advanced healthcare interventions.
- Apollo Hospitals, Greams Road, achieved a significant milestone by completing 6,000 robotic surgeries, reinforcing its leadership in medical technology.
- A rare single-hole robotic surgery was successfully conducted at Apollo Hospitals for the treatment of a gallbladder-related illness, demonstrating cutting-edge surgical techniques.
- Apollo Children's Hospital in Chennai introduced the Fontan procedure, a ground-breaking treatment to treat congenital heart disease, further enhancing paediatric care.
- In Hyderabad, Apollo Hospitals performed advanced mechanical thrombectomy on four brain stroke patients within 24 hours, highlighting its expertise in stroke management.
- Apollo Hospitals continues to boost medical tourism, strengthening its global position as a healthcare destination for advanced treatments.

NEW LAUNCHES, INITIATIVES AND PARTNERSHIPS

- The Government signed an MoU with Apollo Hospitals to provide free treatment for children with heart disease, as announced by the Tripura Chief Minister.
- Apollo Hospitals inaugurated a new multi-speciality hospital in Chirala, expanding its footprint and providing advanced healthcare facilities to the region.
- Apollo Prostate Institute introduced water vapor thermotherapy for the treatment of enlarged prostate, marking another innovation in urological care.
- Apollo's Bengaluru cancer unit launched a robotic radiosurgery system for advanced tumour treatment, further enhancing its oncology services.
- A new Breast Clinic was launched at Apollo Hospitals, Madurai, aimed at providing comprehensive care for breast health.
- Apollo Hospitals published a book outlining safety protocols to protect staff, patients, and visitors, emphasizing its focus on patient and healthcare safety.
- Apollo Hospitals launched a research academy to drive global healthcare innovation, focusing on pioneering medical research and advancements.
- Apollo Hospitals announced the expansion of its robotic surgery program across India, increasing access to cutting-edge surgical care.

AWARDS AND ACCOLADES

- Apollo Hospitals Bhubaneswar has been honored as No. 1 in Nephrology and Bariatrics by Times Health Icon Odisha 2024.
- Apollo Hospitals has won numerous awards at Times Network India Health Awards 2024, including The Best Multi-Specialty Hospital Group in India.
- Apollo Hospitals Navi Mumbai is honored to be recognized as the Best Super Specialty Hospital in Mumbai at the NavaBharath Healthcare Awards 2024.



About Apollo

Apollo revolutionized healthcare when Dr Prathap Reddy opened the first hospital in Chennai in 1983. Today Apollo is the world's largest integrated healthcare platform with over 10,000 beds across 73 hospitals, over 6000 pharmacies and over 2500 clinics and diagnostic centers as well as 500+ telemedicine centres. Since its inception, Apollo has emerged as one of the world's premier cardiac having conducted over 300,000 angioplasties and over 200,000 surgeries. Apollo continues to invest in research to bring the most cutting-edge technologies, equipment and treatment protocols to ensure patients have the best available care in the world. Apollo's 100,000 family members are dedicated to bringing you the best care and leaving the world better than we found it.

For further details, log onto: www.apollohospitals.com

For further information, please contact:

For Media / Investors

R Krishnakumar
Apollo Hospitals Ltd.
Krishnakumar_r@apollohospitals.com
+91 44 2829 7840

Mayank Vaswani
CDR India
mayank@cdr-india.com
+91 22 6645 1230

Disclaimer

Some of the statements in this document that are not historical facts are forward looking statements. These forward looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.

These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.

Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.